A carregar...
Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity
Anti-CD20 therapy using rituximab directly targeting B cells has been approved for treatment of non-Hodgkin lymphoma, rheumatoid arthritis and anti-neutrophil cytoplasmic antibody-associated vasculitides and has led to reappreciation of B-lineage cells for anti-rheumatic treatment strategies. Moreov...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3535716/ https://ncbi.nlm.nih.gov/pubmed/23281743 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/ar3909 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|